2023 World Conference on Lung Cancer (Posters)-EP07.05. Neoadjuvant Chemotherapy or Chemo-IO in Resectable KRAS-Mutated Non-small Cell Lung Cancer (NSCLC) Patients: Single Center Experience

EP07.05. Neoadjuvant Chemotherapy or Chemo-IO in Resectable KRAS-Mutated Non-small Cell Lung Cancer (NSCLC) Patients: Single Center Experience - PDF(Slides)

Back to course

Pdf Summary

This study examined the outcomes of neoadjuvant chemotherapy or chemo-immunotherapy in patients with resectable KRAS-mutated non-small cell lung cancer (NSCLC). The researchers analyzed data from patients treated at MD Anderson Cancer Center between January 2011 and January 2023. They assessed major pathological response (MPR), pathological complete response (pCR), event-free survival (EFS), and overall survival (OS) in these patients.<br /><br />The results showed that neoadjuvant chemotherapy with or without immunotherapy was associated with longer EFS and OS compared to chemotherapy alone in patients with resectable KRAS-mutated NSCLC. MPR was also associated with improved EFS and OS in these patients. Furthermore, patients with KRAS G12C mutations had a higher MPR rate and longer EFS and OS compared to those with non-KRAS G12C mutations. On the other hand, STK11 co-mutation was associated with a lower MPR rate and shorter EFS and OS.<br /><br />Overall, the study suggests that neoadjuvant chemotherapy or chemo-immunotherapy may provide benefits in terms of survival outcomes in patients with resectable KRAS-mutated NSCLC. However, further research is needed to validate these findings and understand the impact of specific mutations, such as KRAS G12C and STK11, on treatment outcomes.<br /><br />This study provides valuable insights into the use of neoadjuvant systemic therapies in patients with resectable KRAS-mutated NSCLC. It highlights the importance of personalized treatment approaches based on molecular characteristics and paves the way for future research in this area.

Asset Subtitle

Kaiwen Wang

Meta Tag

Speaker Kaiwen Wang

Topic Early-Stage NSCLC: Pushing the Boundaries

Keywords

neoadjuvant chemotherapy

chemo-immunotherapy

KRAS-mutated non-small cell lung cancer

MD Anderson Cancer Center

major pathological response

pathological complete response

event-free survival

overall survival

KRAS G12C mutations

STK11 co-mutation